Vanguard Group Inc Clene Inc. Transaction History

Vanguard Group Inc

$4.96 Trillion
Q1 2024

A detailed history of Vanguard Group Inc transactions in Clene Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 2,619,703 shares of CLNN stock, worth $969,290. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,619,703

Previous 2,618,388 0.05%

Holding current value

$969,290

Previous $785,000 43.44%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$0.28 - $0.53 $368 - $696	1,315 Added 0.05%	2,619,703 $1.13 Million
Q4 2023 Feb 14, 2024	BUY	$0.26 - $0.55 $44,842 - $94,859	172,471 Added 7.05%	2,618,388 $785,000
Q3 2023 Nov 14, 2023	BUY	$0.46 - $0.87 $112,948 - $213,619	245,540 Added 11.16%	2,445,917 $1.22 Million
Q2 2023 Aug 14, 2023	BUY	$0.78 - $1.22 $842,088 - $1.32 Million	1,079,601 Added 96.33%	2,200,377 $1.94 Million
Q1 2023 May 15, 2023	BUY	$0.95 - $1.62 $179,282 - $305,723	188,718 Added 20.25%	1,120,776 $1.27 Million

Q4 2022 Feb 10, 2023	BUY	$0.92 - $1.11 $409 - $493	445 Added 0.05%	932,058 $932,000
Q3 2022 Nov 14, 2022	BUY	$0.33 - $4.83 $39,297 - $575,175	119,084 Added 14.66%	931,613 $2.61 Million
Q2 2022 Aug 12, 2022	BUY	$2.1 - $4.12 $47,388 - $92,971	22,566 Added 2.86%	812,529 $2.05 Million
Q1 2022 May 13, 2022	SELL	$2.42 - $4.42 $529,670 - $967,414	-218,872 Reduced 21.7%	789,963 $3.11 Million
Q4 2021 Feb 14, 2022	SELL	$3.95 - $7.53 $454,992 - $867,365	-115,188 Reduced 10.25%	1,008,835 $4.14 Million
Q3 2021 Nov 12, 2021	SELL	$6.83 - $13.58 $55,042 - $109,441	-8,059 Reduced 0.71%	1,124,023 $7.68 Million
Q2 2021 Aug 13, 2021	BUY	$6.98 - $13.33 $7.9 Million - $15.1 Million	1,132,082 New	1,132,082 $12.7 Million

Others Institutions Holding CLNN

# of Institutions

Shares Held

7.44M

Call Options Held

48.1K

Put Options Held

160K

View Full List

About Clene Inc.

Ticker CLNN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 63,502,000
Market Cap $23.5M
Description
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral scleros...

More about CLNN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Clene Inc. Transaction History